Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin

Journal of the National Cancer Institute

Volumn 81, Issue 19, 1989, Pages 1464-1471

  Mangioni, C ^a   Bolis, G ^b   Pecorelli, S ^c   Bragman, K ^d   Epis, A ^a   Favalli, G ^c   Gambino, A ^c   Landoni, F ^a   Presti, M ^b   Torri, W ^e   Vassena, L ^a   Zanaboni, F ^b   Marsoni, S ^e  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN;

ADVANCED CANCER; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMAN; MIDDLE AGE; MULTICENTER STUDIES; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROGNOSIS; RANDOM ALLOCATION; REMISSION INDUCTION; SUPPORT, NON-U.S. GOV'T;

EID: 0024465181     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/81.19.1464     Document Type: Article

References (30)

1. ROSENBERG B: Anticancer activity of m-dichlorodiammineplatinum(II) and some relevant chemistry. Cancer Treat Rep 63:1433-1438, 1979
2. SESSA C: European studies with cisplatin and cisplatin analogs in advanced ovarian cancer. Eur J Cancer Clin Oncol 22:1271-1277, 1986
3. OZOLS RF, YOUNG RC: High-dose cisplatin therapy in ovarian cancer. Semin Oncol 12(suppl):21-30, 1985
4. OZOLS RF, CORDEN BJ, JACOB J, et al: High-dose cisplatin in hypertonic saline. Ann Intern Med 100:19-24, 1984
5. BRUCKNER HW, WALLACH R, COHEN CJ, et al: High-dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol 12:64-67, 1981
6. HAYES DM, CVITKOVIC E, GOLBEY RB, et al: High dose cis-platinum diammine dichloride: Amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372-1381, 1977
7. HARRAP KR, JONES M, WILKINSON CR, et al: Anti-tumor, toxic and biochemical properties of cisplatin and eight other platinum complexes. In Cisplatin: Current Status and New Developments (Prestayko AW, Crooke ST, Carter SK, eds). New York: Academic Press, 1980, pp 193-212
8. CALVERT AH, HARLAND SJ, NEWELL DR, et al: Early clinical studies with c£s-diammine-l, l-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140-147, 1982
9. EVANS BD, RAJU KS, CALVERT AH, et al: Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep 67:997-1000, 1983
10. MARSONI S, BOLIS G, EPIS A, et al: A phase II trial of carboplatin (CBDCA; NSC 241240) in advanced ovarian cancer patients (OACP). In Abstracts of Lecture Symposia and Free Communications: 14th International Cancer Congress, August 21-27, 1986, Budapest, Hungary (Akademivi Kiedv, ed), vol. 3. Basel: S Karger, 1986, p 1004
11. WILTSHAW E, EVANS BD, JONES AC, et al: JMS, successor to cisplatin in advanced ovarian carcinoma? Lancet 1:587, 1983
12. WILTSHAW E, EVANS B, HARLAND S: Phase III randomized trial cisplatin versus JM8 (carboplatin) in 112 ovarian cancer patients, stage III and IV. Proc ASCO 4:121, 1985
13. EISENHAUER EA, SWENERTON KD, STURGEON JF, et al: Phase II study of carboplatin in patients with ovarian carcinoma: A National Cancer Institute of.Canada Clinical Trials Group study. Cancer Treat Rep 70:1195-1198, 1986
14. Gruppo InteregionaleCooperativo Oncologico Ginecologico(GICOG): Randomized comparison of cisplatin with cyclophosphamide/cisplaiin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 2:353-359, 1987
15. NEUT JP, TEN BOKKEL HUININK WW, VAN DER BURG ME, et al: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 5:1157-1168, 1987
16. TOMIROTTI M, PERRONE S, GIE P, et al: Cisplatin (CP) versus cyclophosphamide, Adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: A prospective randomized trial. Tumori 74:575-577, 1988
17. WILTSHAW E, EVANS B, RUSTIN G, et al: A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian cancer. J Clin Oncol 4:722-729, 1986
18. MILLER HB, HOOGSTRATEN B, STAQUET M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
19. KAPLAN EL, MEIER P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. TARONE RE, WARE J: On distribution-free tests for equality of cervical distributions. Biometrika 64:156-160, 1977
21. Cox DR: Regression models and life tables. J R Stat Soc 34:187-202, 1972
22. Cox DR: Analysis of Binary Data. London: Methuen, 1970, pp 18-19
23. LEVIN L, HRYNIUK WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756-767, 1987
24. GORE ME, WILTSHAW E, DAWSON T, et al: Non-cross resistance between cisplatin and carboplatin in ovarian cancer. Proc ASCO 6:117, 1987
25. CONTE PF, BRUZZONE M, CHIARA S, et al: A randomized study comparing carboplatin (CBDCA), doxorubicin (DX) and Cytoxan (C) CAC versus cisplatin DDP, doxorubicin and Cytoxan (PAC) in stage III-IV ovarian cancer. Proc ASCO 6:118, 1987
26. TEN BOKKEL HUININK WW, VAN DER BURG ME, et al: Carboplatin replacing cisplatin in combination chemotherapy. A large scale randomized phase III trial of the gynecological cancer cooperative group of EORTC. Proc ASCO 6:118, 1987
27. TRUMP D, GREM JL, TUTSCH KD, et al: Platinum analogue combination chemotherapy: Cisplatin and carboplatin—a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J Clin Oncol 5:1281-1289, 1987
28. EDMONSON JH, MCCORMACK GM, WIEAND HS, et al: Comparison of cyclophosphamide (CYCLO) + carboplatin (CBDCA) vs. cyclo+ cisplatin (CDDP) in stage III and IV ovarian carcinoma. Proc ASCO 7:137, 1988
29. OZOLS RF, OSTCHEGA Y, CURT G, et al: High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 5:197-201, 1987
30. VON HOFF D: Whither carboplatin? A replacement for or an alternative to cisplatin? J Clin Oncol 5:169-171, 1987